Published in Biomed Res Int on September 05, 2013
Alternative splicing of endothelial fibronectin is induced by disturbed hemodynamics and protects against hemorrhage of the vessel wall. Arterioscler Thromb Vasc Biol (2014) 1.48
The TLR4 agonist fibronectin extra domain A is cryptic, exposed by elastase-2; use in a fibrin matrix cancer vaccine. Sci Rep (2015) 0.80
Immunotherapy based on dendritic cells pulsed with CTPFoxM1 fusion protein protects against the development of hepatocellular carcinoma. Oncotarget (2016) 0.75
Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med (2001) 9.70
Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A (2002) 6.19
Avidin and streptavidin. Methods Enzymol (1990) 5.47
Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 5.37
A monovalent streptavidin with a single femtomolar biotin binding site. Nat Methods (2006) 3.89
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol (2007) 3.42
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 3.14
On regulation of phagosome maturation and antigen presentation. Nat Immunol (2006) 3.11
HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med (1997) 3.03
Dendritic cell survival and maturation are regulated by different signaling pathways. J Exp Med (1998) 2.66
Intensified and protective CD4+ T cell immunity in mice with anti-dendritic cell HIV gag fusion antibody vaccine. J Exp Med (2006) 2.53
Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity (2002) 2.47
Antigenic targeting of the human mannose receptor induces tumor immunity. J Immunol (2007) 1.93
Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J Intern Med (2012) 1.56
Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect Immun (2004) 1.49
The properties of subunits of avidin coupled to sepharose. Biochem J (1973) 1.42
TLR signalling and the function of dendritic cells. Chem Immunol Allergy (2005) 1.39
Plasmacytoid dendritic cells efficiently cross-prime naive T cells in vivo after TLR activation. Blood (2008) 1.32
Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity. Eur J Immunol (2000) 1.24
Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem (2007) 1.23
The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol (2007) 1.08
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res (2011) 1.06
The immunogenicity of CpG-antigen conjugates. Adv Drug Deliv Rev (2009) 0.97
Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells. J Immunol (2008) 0.96
A CD91-positive subset of CD11c+ blood dendritic cells: characterization of the APC that functions to enhance adaptive immune responses against CD91-targeted antigens. J Immunol (2004) 0.92
CD40-targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine (2003) 0.91
In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models. J Immunother (2007) 0.87
Tumor cells engineered to codisplay on their surface 4-1BBL and LIGHT costimulatory proteins as a novel vaccine approach for cancer immunotherapy. Cancer Gene Ther (2010) 0.86
Eradication of large tumors expressing human papillomavirus E7 protein by therapeutic vaccination with E7 fused to the extra domain a from fibronectin. Int J Cancer (2011) 0.85
Immunization against hepatitis C virus with a fusion protein containing the extra domain A from fibronectin and the hepatitis C virus NS3 protein. J Hepatol (2009) 0.84
Circulating specific antibodies enhance systemic cross-priming by delivery of complexed antigen to dendritic cells in vivo. Eur J Immunol (2012) 0.84
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol (2005) 10.27
A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med (2006) 3.21
AIF deficiency compromises oxidative phosphorylation. EMBO J (2004) 3.19
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol (2013) 2.63
A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences. Nucleic Acids Res (2006) 2.38
Molecular basis of xeroderma pigmentosum group C DNA recognition by engineered meganucleases. Nature (2008) 2.37
Efficient targeting of a SCID gene by an engineered single-chain homing endonuclease. Nucleic Acids Res (2009) 2.14
Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med (2011) 2.04
Engineering of large numbers of highly specific homing endonucleases that induce recombination on novel DNA targets. J Mol Biol (2005) 2.04
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Apoptosis regulation in tetraploid cancer cells. EMBO J (2006) 1.89
Ae2a,b-deficient mice develop antimitochondrial antibodies and other features resembling primary biliary cirrhosis. Gastroenterology (2008) 1.87
Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients. Gastroenterology (2005) 1.75
Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Inhibiting expression of specific genes in mammalian cells with 5' end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc Natl Acad Sci U S A (2003) 1.55
Cardiotrophin-1 reduces ischemia/reperfusion injury during liver transplant. J Surg Res (2012) 1.45
Amphiregulin: an early trigger of liver regeneration in mice. Gastroenterology (2005) 1.44
Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells. Hepatology (2011) 1.44
Biliary secretion of S-nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat. Hepatology (2010) 1.41
Up-regulation of microRNA 506 leads to decreased Cl-/HCO3- anion exchanger 2 expression in biliary epithelium of patients with primary biliary cirrhosis. Hepatology (2012) 1.38
[Influence of hospital type on treatment and prognosis in patients with non-ST elevation acute coronary syndrome]. Rev Esp Cardiol (2010) 1.37
The tight junction-associated protein occludin is required for a postbinding step in hepatitis C virus entry and infection. J Virol (2009) 1.36
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology (2007) 1.32
Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing. J Virol (2006) 1.32
The epidermal growth factor receptor: a link between inflammation and liver cancer. Exp Biol Med (Maywood) (2009) 1.31
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
Immune response against dying tumor cells. Adv Immunol (2004) 1.26
Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. J Hepatol (2005) 1.23
Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology (2008) 1.23
Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res (2008) 1.21
The epidermal growth factor receptor ligand amphiregulin participates in the development of mouse liver fibrosis. Hepatology (2008) 1.20
Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol (2002) 1.19
Novel role for amphiregulin in protection from liver injury. J Biol Chem (2005) 1.19
Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus. Nucleic Acids Res (2010) 1.19
Topical application of a peptide inhibitor of transforming growth factor-beta1 ameliorates bleomycin-induced skin fibrosis. J Invest Dermatol (2005) 1.18
Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol (2010) 1.17
Bicarbonate-rich choleresis induced by secretin in normal rat is taurocholate-dependent and involves AE2 anion exchanger. Hepatology (2006) 1.16
Homing endonucleases: from basics to therapeutic applications. Cell Mol Life Sci (2010) 1.16
Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ. Cancer Immunol Immunother (2010) 1.15
Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res (2006) 1.14
Low surface expression of B7-1 (CD80) is an immunoescape mechanism of colon carcinoma. Cancer Res (2006) 1.14
Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas. J Clin Oncol (2004) 1.13
Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol (2003) 1.13
Liver transplant recipients older than 60 years have lower survival and higher incidence of malignancy. Am J Transplant (2003) 1.13
Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats. Hepatology (2010) 1.12
Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab (2011) 1.12
Anion exchanger 2 is essential for spermiogenesis in mice. Proc Natl Acad Sci U S A (2003) 1.11
The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo. J Immunol (2007) 1.08
A synthetic peptide from transforming growth factor beta type III receptor inhibits liver fibrogenesis in rats with carbon tetrachloride liver injury. Cytokine (2003) 1.08
De Novo neoplasia after liver transplantation: an analysis of risk factors and influence on survival. Liver Transpl (2005) 1.07
A synthetic peptide from transforming growth factor-beta1 type III receptor prevents myocardial fibrosis in spontaneously hypertensive rats. Cardiovasc Res (2008) 1.07
Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer. J Hepatol (2007) 1.06
Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Res (2011) 1.06
A novel lung cancer signature mediates metastatic bone colonization by a dual mechanism. Cancer Res (2008) 1.05
Gene therapy of cancer with interleukin-12. Curr Pharm Des (2003) 1.04
Development of a liver-specific Tet-on inducible system for AAV vectors and its application in the treatment of liver cancer. Mol Ther (2011) 1.03
A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol (2010) 1.03
Cardiotrophin-1 defends the liver against ischemia-reperfusion injury and mediates the protective effect of ischemic preconditioning. J Exp Med (2006) 1.02
Expression of Wilms' tumor suppressor in the liver with cirrhosis: relation to hepatocyte nuclear factor 4 and hepatocellular function. Hepatology (2003) 1.01
Crystal structure of I-DmoI in complex with its target DNA provides new insights into meganuclease engineering. Proc Natl Acad Sci U S A (2008) 1.01
Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library. Cytokine (2007) 1.01
Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen. Clin Cancer Res (2002) 1.01